Medicine
October 9, 2026 · via Europe PMC
Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma: A case report.
Zhang J, Chen CQ, Huang H, Yao ZC, Qin X, Wei FF
AI summary — for doctors, generated from the abstract only
One patient with heavily pretreated metastatic clear cell renal carcinoma survived about 6 years with sequential therapy including checkpoint inhibitor plus bevacizumab, but a single case cannot establish efficacy.
What was studied
A case report of a 49-year-old man with stage IV clear cell RCC who progressed through nephrectomy, sorafenib, radiotherapy, sunitinib plus interleukin-2, then received camrelizumab plus bevacizumab followed by tislelizumab plus bevacizumab.
Key findings
- Disease was progressing with lung, adrenal and brain metastases before the checkpoint inhibitor plus bevacizumab regimen.
- He reached sustained stable disease with overall survival of about 6 years.
- The authors describe the treatment as well tolerated.
Clinical relevance
It illustrates that long disease control can occasionally be achieved in later-line metastatic RCC, relevant to oncologists discussing sequencing options.
Who should care
Limitations
A single, selected patient with many prior therapies makes it impossible to attribute the outcome to the combination, and there is no comparator.
This does not change practice; it supports further prospective study of checkpoint inhibitor plus bevacizumab in pretreated disease.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
RATIONALE
Renal cell carcinoma is a highly heterogeneous urological malignancy, with clear cell renal cell carcinoma (ccRCC) as the most common pathological subtype. A considerable proportion of patients are diagnosed at advanced stages or experience postoperative recurrence and distant metastasis, leading to poor long-term prognosis. Although targeted therapy and immune checkpoint inhibitors (ICIs) have greatly improved the treatment landscape of advanced ccRCC, optimal sequential and combination treatment strategies for heavily pretreated metastatic patients remain to be further explored.
PATIENT CONCERNS
A 49-year-old male patient was diagnosed with stage IV ccRCC complicated with lung metastasis. After palliative nephrectomy and multiple lines of targeted and immunotherapeutic regimens, the patient still suffered from continuous tumor progression, with recurrent pulmonary metastatic lesions, newly occurring adrenal metastasis and brain metastasis, accompanied by clinical symptoms including cough, hemoptysis, and persistent dizziness.
DIAGNOSES
The patient was definitively diagnosed with metastatic ccRCC (T1N1M1, Stage IV). Radiological examinations confirmed progressive pulmonary metastases, new right adrenal metastasis, and right frontal lobe brain metastasis after multiple lines of treatment.
INTERVENTIONS
The patient initially underwent palliative left nephrectomy and sequential sorafenib targeted therapy. After disease progression, intracranial intensity-modulated radiotherapy combined with sunitinib plus interleukin-2 immunotherapy was administered. Following subsequent disease progression, the patient received 4 cycles of camrelizumab combined with bevacizumab, followed by bevacizumab maintenance therapy. Since January 2024, the patient has been treated with tislelizumab plus bevacizumab combination regimen.
OUTCOMES
After sequential multi-line individualized treatment, the patient achieved sustained stable disease. The overall survival of the patient has reached approximately 6 years up to the latest follow-up, with favorable long-term survival benefit and well-tolerated treatment safety.
LESSONS
For heavily pretreated metastatic ccRCC patients with prior targeted therapy but no previous ICI exposure, ICI combined with bevacizumab is a feasible and effective salvage treatment regimen, which can achieve durable survival benefits. Further prospective clinical studies and long-term follow-up are required to verify the clinical promotion value of this combination strategy.
DOI
10.1097/MD.0000000000051079
PMID
42854072
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed